This is a type of chronic leukemia involving B-cells. It's often slow-growing but can sometimes become more serious.
Every report comes from a Lived member, sent anonymously.
Have you tried Imbruvica (Ibrutinib) for CLL (Chronic Lymphocytic Leukemia)?
Chronic lymphocytic leukemia (CLL) is a cancer of B lymphocytes, the white blood cells that normally make antibodies. The bone marrow produces abnormal B cells that gradually build up in the blood, bone marrow, lymph nodes and spleen. Over time they can crowd out healthy blood cells, leading to anemia, easy bleeding and infections, and the abnormal cells themselves are poor at fighting infection. CLL usually progresses slowly. Many people have no symptoms when it is found, often on a routine blood test, and do not need treatment right away. When symptoms appear, they can include painless swollen lymph nodes in the neck, armpits or groin, tiredness and a feeling of fullness below the ribs from an enlarged spleen. When the same disease shows up mainly in the lymph nodes rather than the blood, it is called small lymphocytic lymphoma (SLL), and it is treated the same way. CLL is one of the most common leukemias in adults, and most people are diagnosed around age 70.
CLL begins with changes in the DNA of developing B cells in the bone marrow. What causes those changes is not known, so there is no reliable way to predict who will get it. Age is the strongest risk factor: most people are diagnosed after 50, and men are affected nearly twice as often as women. CLL is also more common in white people than in other racial and ethnic groups. Having a close relative with CLL or another blood cancer raises the risk. Even so, CLL is not inherited in a predictable way, and genetic testing of family members is not recommended. Exposure to certain chemicals, including Agent Orange used in the Vietnam War, has also been linked to CLL. These factors raise the odds but do not mean a particular person will develop it.
CLL is often first suspected when a complete blood count (CBC), a routine test that counts the different blood cells, shows a high number of lymphocytes. The diagnosis is confirmed with flow cytometry, a test on a blood sample that identifies the abnormal B cells by the markers on their surface. CLL is diagnosed when these cells reach at least 5,000 per microliter of blood. A smaller number of the same kind of cells, without swollen lymph nodes or symptoms, is called monoclonal B-cell lymphocytosis (MBL). It is a precursor rather than CLL, and only about 1% of people with the higher-count form go on to need CLL treatment each year. Staging relies on a physical exam and blood counts rather than scans. The two staging systems, Rai and Binet, ask whether lymph nodes, the spleen or the liver are enlarged and whether the marrow has become crowded enough to cause anemia or a low platelet count. Low red cells or platelets indicate more advanced disease. When treatment is being considered, the leukemia cells are tested for features that shape the choice. Changes in the TP53 gene, including a missing piece of chromosome 17 (17p deletion), make the disease respond poorly to chemotherapy, so they are checked before each new treatment. IGHV status, a feature of the cells' antibody gene, needs checking only once: CLL with unmutated IGHV tends to progress faster. Scans and a bone marrow biopsy are needed only in particular situations.
Early CLL that causes no symptoms is usually not treated. Instead, people are monitored with regular checkups and blood counts, an approach called active surveillance or watch and wait. Trials have shown that starting treatment early, even with modern drugs, does not help people live longer. Treatment begins when the disease becomes active: for example, when anemia or low platelets develop, lymph nodes or the spleen become very large or uncomfortable, the lymphocyte count climbs very quickly, or the leukemia causes significant symptoms. Most treatment now uses targeted drugs rather than traditional chemotherapy, in two main approaches. BTK inhibitors block Bruton tyrosine kinase (BTK), an enzyme that the leukemia cells rely on to grow. They are pills taken every day for as long as they keep working, which is often many years. Acalabrutinib (Calquence) and zanubrutinib (Brukinsa) are generally preferred over the older ibrutinib (Imbruvica) because they cause fewer heart side effects. All of these can increase bleeding and can trigger heart rhythm problems such as atrial fibrillation, so heart history and the need for blood thinners weigh heavily in choosing them. The second approach is a fixed course built around venetoclax (Venclexta), a pill that blocks BCL-2, a protein that helps CLL cells survive. It is commonly combined with obinutuzumab (Gazyva), an antibody given by infusion, for about a year, or with a BTK inhibitor for a little over a year, and then stopped. Because venetoclax can kill many leukemia cells quickly, the dose is raised gradually over five weeks, with extra fluids, frequent blood tests and medicine to prevent tumor lysis syndrome, a dangerous chemical imbalance that can damage the kidneys when many cells break down at once. For people without TP53 changes, guidelines favor these fixed-duration treatments; with TP53 changes, continuous BTK inhibitor treatment is often preferred. Older chemotherapy combinations are now rarely recommended when targeted options are available. If CLL comes back or stops responding, other targeted drugs, clinical trials and, for selected people, a stem cell transplant are options. For most people, treatment controls CLL rather than eliminating it, and the disease can return after a period of remission.
The course of CLL differs widely. For some people it stays stable for many years without treatment; for others it progresses and needs treatment sooner. Features such as IGHV status and TP53 changes help predict which path is more likely, but they cannot say exactly what will happen to one person. In the United States, about 90% of people diagnosed with CLL survive the effects of their leukemia for at least five years, a figure based on large groups that cannot predict an individual outcome. Living with untreated leukemia can be unsettling, and some people describe watch and wait as watch, wait and worry. Regular follow-up with blood counts is how changes are caught, and how often visits are needed depends on how active the disease is. A long-term relationship with a hematologist or oncologist helps. Because CLL weakens the immune system over time, infections are one of the main health concerns, whether or not someone is being treated. Recommended vaccines include those against pneumococcal pneumonia, shingles (the nonlive Shingrix vaccine), hepatitis B, flu and COVID-19, even though they may work less well than usual. Live vaccines, such as measles-mumps-rubella and yellow fever, should be avoided. Good hand hygiene lowers the risk without the need to give up social life. People with CLL also have a higher risk of other cancers, particularly skin cancer, even before any treatment. Sun protection, regular skin checks, not smoking and keeping up with usual cancer screening are worthwhile. Less often, the immune system attacks the body's own red cells or platelets, and in about 2% to 10% of people CLL changes into a fast-growing lymphoma, called Richter transformation, which needs different treatment.
Arrange a medical visit if a blood test shows a raised lymphocyte count, or if swollen lymph nodes, tiredness or fullness below the ribs persist. If you already have CLL, contact your care team before your next scheduled visit if you develop drenching night sweats, fevers without an obvious infection, unexplained weight loss, lymph nodes that grow quickly, or new easy bruising, tiny red spots on the skin or unusual bleeding. These can mean the disease is becoming active or, less often, has changed into a faster-growing lymphoma. Call your care team promptly about a fever or signs of a significant infection, such as a cough with shortness of breath, because CLL and its treatment make serious infections more likely and they are best treated early. If you take a BTK inhibitor, report palpitations, dizziness or fainting, and tell the team before any planned surgery or before starting a blood thinner.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with CLL (Chronic Lymphocytic Leukemia) is like, what's helped you, or ask the community a question.